CN101732264A - 一种头孢西酮钠冻干粉针剂及其制备方法 - Google Patents
一种头孢西酮钠冻干粉针剂及其制备方法 Download PDFInfo
- Publication number
- CN101732264A CN101732264A CN201010022008A CN201010022008A CN101732264A CN 101732264 A CN101732264 A CN 101732264A CN 201010022008 A CN201010022008 A CN 201010022008A CN 201010022008 A CN201010022008 A CN 201010022008A CN 101732264 A CN101732264 A CN 101732264A
- Authority
- CN
- China
- Prior art keywords
- merck
- refosporin
- injection
- cefazedone
- powder injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 title claims abstract description 59
- 238000002347 injection Methods 0.000 title claims abstract description 46
- 239000007924 injection Substances 0.000 title claims abstract description 46
- 229960005312 cefazedone Drugs 0.000 title abstract description 51
- VTLCNEGVSVJLDN-MLGOLLRUSA-N cefazedone Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3C=C(Cl)C(=O)C(Cl)=C3)[C@H]2SC1 VTLCNEGVSVJLDN-MLGOLLRUSA-N 0.000 title abstract description 51
- 238000002360 preparation method Methods 0.000 title description 37
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 13
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 12
- 229930195725 Mannitol Natural products 0.000 claims abstract description 12
- 239000000594 mannitol Substances 0.000 claims abstract description 12
- 235000010355 mannitol Nutrition 0.000 claims abstract description 12
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960001305 cysteine hydrochloride Drugs 0.000 claims abstract description 9
- 239000004475 Arginine Substances 0.000 claims abstract description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 7
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 7
- 229960003180 glutathione Drugs 0.000 claims abstract description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 5
- 239000008101 lactose Substances 0.000 claims abstract description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 4
- 229960003121 arginine Drugs 0.000 claims abstract description 4
- KPHCAENKLGZHCB-VQZRABBESA-M sodium;(6r,7r)-7-[[2-(3,5-dichloro-4-oxopyridin-1-yl)acetyl]amino]-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3C=C(Cl)C(=O)C(Cl)=C3)[C@H]2SC1 KPHCAENKLGZHCB-VQZRABBESA-M 0.000 claims description 38
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 230000003078 antioxidant effect Effects 0.000 claims description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- 235000003969 glutathione Nutrition 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 235000015165 citric acid Nutrition 0.000 claims description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 4
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 4
- 235000019800 disodium phosphate Nutrition 0.000 claims description 4
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 4
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical compound CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000126 substance Substances 0.000 abstract description 20
- 229920000642 polymer Polymers 0.000 abstract description 19
- 238000003860 storage Methods 0.000 abstract description 4
- 239000012535 impurity Substances 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 2
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 abstract 1
- 108010024636 Glutathione Proteins 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 20
- 238000005516 engineering process Methods 0.000 description 15
- 238000004108 freeze drying Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000008215 water for injection Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 229930186147 Cephalosporin Natural products 0.000 description 7
- 229940124587 cephalosporin Drugs 0.000 description 7
- 150000001780 cephalosporins Chemical class 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 238000005304 joining Methods 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 241000283977 Oryctolagus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005262 decarbonization Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- PMZBHPUNQNKBOA-UHFFFAOYSA-N 5-methylbenzene-1,3-dicarboxylic acid Chemical compound CC1=CC(C(O)=O)=CC(C(O)=O)=C1 PMZBHPUNQNKBOA-UHFFFAOYSA-N 0.000 description 1
- 241000360771 Coreana Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- NKZMPZCWBSWAOX-IBTYICNHSA-M Sulbactam sodium Chemical compound [Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)N2C(=O)C[C@H]21 NKZMPZCWBSWAOX-IBTYICNHSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
- 229960003408 cefazolin sodium Drugs 0.000 description 1
- ZQQALMSFFARWPK-ZTQQJVKJSA-L cefotetan disodium Chemical compound [Na+].[Na+].N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C([O-])=O)=O)C(=O)C1SC(=C(C(N)=O)C([O-])=O)S1 ZQQALMSFFARWPK-ZTQQJVKJSA-L 0.000 description 1
- 229960004445 cefotetan disodium Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 208000019836 digestive system infectious disease Diseases 0.000 description 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
- 229950009041 edaravone Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- JPJKQVVKHIZICB-UHFFFAOYSA-M sodium;8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1=CCSC2CC(=O)N12 JPJKQVVKHIZICB-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 229960000614 sulbactam sodium Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010022008XA CN101732264B (zh) | 2010-01-06 | 2010-01-06 | 一种头孢西酮钠冻干粉针剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010022008XA CN101732264B (zh) | 2010-01-06 | 2010-01-06 | 一种头孢西酮钠冻干粉针剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101732264A true CN101732264A (zh) | 2010-06-16 |
CN101732264B CN101732264B (zh) | 2012-07-04 |
Family
ID=42456638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010022008XA Expired - Fee Related CN101732264B (zh) | 2010-01-06 | 2010-01-06 | 一种头孢西酮钠冻干粉针剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101732264B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103860563A (zh) * | 2012-12-18 | 2014-06-18 | 四川科伦药业股份有限公司 | 含头孢妥仑钠的药物组合物 |
CN105125557A (zh) * | 2015-09-11 | 2015-12-09 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗感染性疾病的药物头孢西酮钠组合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1823738A (zh) * | 2005-12-21 | 2006-08-30 | 贵州圣济堂制药有限公司 | 注射用粉针剂及其制备方法 |
CN101049312B (zh) * | 2006-04-07 | 2010-09-15 | 黄金秀 | 一种药物组合物、其制备方法及其用途 |
CN101584671B (zh) * | 2009-07-17 | 2011-03-16 | 山东罗欣药业股份有限公司 | 一种头孢西酮钠药物粉针剂以及头孢西酮钠原料药的合成方法 |
-
2010
- 2010-01-06 CN CN201010022008XA patent/CN101732264B/zh not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103860563A (zh) * | 2012-12-18 | 2014-06-18 | 四川科伦药业股份有限公司 | 含头孢妥仑钠的药物组合物 |
CN103860563B (zh) * | 2012-12-18 | 2016-07-06 | 四川科伦药业股份有限公司 | 含头孢妥仑钠的药物组合物 |
CN105125557A (zh) * | 2015-09-11 | 2015-12-09 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗感染性疾病的药物头孢西酮钠组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN101732264B (zh) | 2012-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102180890B (zh) | 头孢硫脒结晶物及其用途 | |
CN101317852B (zh) | 一种复方甘草酸苷类粉针注射剂及其制备方法 | |
CN101559040A (zh) | 一种盐酸头孢替安的药物组合物及其制剂 | |
CN101011397A (zh) | 泮托拉唑钠冻干粉针剂及其制备方法 | |
CN101732264B (zh) | 一种头孢西酮钠冻干粉针剂 | |
CN101904822B (zh) | 一种法罗培南钠冻干粉针及其制备方法 | |
CN101700233B (zh) | 一种戈那瑞林冻干粉针剂的制备方法 | |
CN103110640B (zh) | 一种注射用头孢唑肟钠和复方氨基酸注射液的药物组合物 | |
CN101297809B (zh) | 头孢哌酮钠与舒巴坦钠混粉的制备方法 | |
CN110393721A (zh) | 头孢噻肟钠药物制剂在经腹部或阴道子宫切除、胃肠道和生殖道等术前预防感染应用 | |
CN102276533A (zh) | 一种新的奥扎格雷钠化合物及其药物组合物 | |
CN103083322B (zh) | 一种注射用盐酸头孢甲肟和复方氨基酸注射液的药物组合物 | |
CN102335114B (zh) | 一种稳定的布洛芬精氨酸注射剂及其制备方法 | |
CN114126583A (zh) | 一种奥硝唑注射液和s-奥硝唑注射液 | |
CN103951679B (zh) | 一种头孢哌酮钠化合物及其药物组合物 | |
CN108670957A (zh) | 一种兽用酸化阿莫西林可溶性粉及其制备方法 | |
CN102988311A (zh) | 一种溶血栓冻干粉针剂及其制备方法 | |
CN108096198A (zh) | 预防和治疗需氧菌与厌氧菌混合感染时的新型抗菌药物组合物及其制备方法 | |
CN102552180B (zh) | 一种克林霉素磷酸酯组合物冻干粉针及其制备方法 | |
CN105748482A (zh) | 一种注射用头孢哌酮钠他唑巴坦钠药物组合物 | |
CN102757471B (zh) | 一种新活性三磷酸胞苷二钠化合物及其药物组合物 | |
CN102670524A (zh) | 一种注射用泮托拉唑钠冻干制剂及其制备方法 | |
CN102697742B (zh) | 注射用盐酸头孢唑兰的制备工艺 | |
CN100453068C (zh) | 含乳酸卡德沙星的注射剂 | |
CN103432086A (zh) | 一种注射用培美曲塞二钠冻干粉针剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: Changsha Yirui Medical Technology Co., Ltd. Document name: Notification of Decision on Request for Restoration of Right |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 283, Furong house, No. two, Furong section, Yuhua Road, Yuhua District, Hunan, Changsha 410007, China 2305 Patentee after: Changsha Yirui Medical Technology Co., Ltd. Address before: Room 410000, Wanxiang enterprise, Station North Road, Hunan, Changsha, 803 Patentee before: Changsha Yirui Medical Technology Co., Ltd. |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Changsha Yirui Medical Technology Co., Ltd. Document name: Notification of Passing Examination on Formalities |
|
ASS | Succession or assignment of patent right |
Owner name: HUNAN AIREN MEDICAL INVESTMENT MANAGEMENT CO., LTD Free format text: FORMER OWNER: CHANGSHA YIRUI MEDICAL TECHNOLOGY CO., LTD. Effective date: 20140507 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 410007 CHANGSHA, HUNAN PROVINCE TO: 410004 CHANGSHA, HUNAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140507 Address after: 6, 410004 floor, five field logistics park, 97 circuit, Tianxin circuit, Tianxin District, Hunan, Changsha Patentee after: Hunan airen medical Cci Capital Ltd Address before: 283, Furong house, No. two, Furong section, Yuhua Road, Yuhua District, Hunan, Changsha 410007, China 2305 Patentee before: Changsha Yirui Medical Technology Co., Ltd. |
|
DD01 | Delivery of document by public notice |
Addressee: Hunan airen medical Cci Capital Ltd Document name: Notification to Pay the Fees |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120704 Termination date: 20180106 |